| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 169.77 | 136.56 |
| Pretax Income | -15.75 | -16.50 |
| Net Income | -15.75 | -16.50 |
| Diluted EPS | -0.13 | -0.14 |
- Net Income YoY
- +4.6%
Key highlights
- Consolidated revenue increased to $169.77 million from $136.56 million in Q3 2025
- Net loss narrowed by 4.6% year-over-year to $15.75 million
- Nine-month revenue reached $478.5 million, up from $403.7 million in the prior year
- Full-year 2026 revenue guidance established at $650 million to $660 million
- Specialty Pharmacy segment remains the primary driver of top-line expansion
How the Period Went
Starling Oncology achieved significant top-line growth in the third quarter of 2026, with revenue rising to $169.77 million from $136.56 million in the same period last year. This 24.3% increase follows a consistent upward trend throughout the fiscal year, with revenue climbing sequentially from $147.4 million in the first quarter and $161.3 million in the second. Profitability metrics also showed moderate improvement; the company reported a net loss of $15.75 million, or $0.13 per diluted share, representing a 4.6% narrowing from the $16.50 million loss recorded in Q3 2025. This performance aligns with a year-to-date revenue total of $478.5 million for the first nine months of 2026.
Margins and Profitability
Despite the robust revenue growth, Starling Oncology remains in a net loss position, reporting a cumulative loss of $28.0 million for the nine months ended September 30, 2026. This ongoing lack of GAAP profitability is reflected in a total stockholders' deficit of $37.4 million. However, the company is trending toward operational break-even on an adjusted basis, according to market data from MarketBeat, which notes a full-year Adjusted EBITDA guidance range of $4 million to $6 million. The Specialty Pharmacy segment has been instrumental in supporting these margins, balancing the higher costs associated with the company’s community clinic infrastructure and its value-based capitated care arrangements.
Business Overview
- Operates a network of community oncology clinics and specialized dispensaries across multiple states
- Utilizes a value-based care model, including capitated arrangements where providers receive fixed fees per patient
- Primary revenue growth is currently driven by the Specialty Pharmacy segment and increased prescription capture rates
- The company rebranded from The Oncology Institute in mid-2026 to reflect its coordinated-care evolution
- Does not maintain an order backlog due to the nature of clinical oncology and pharmaceutical service delivery
- Employs a proprietary technology platform, Starling Nexus, to manage prior authorizations and evidence-based pathways
Financial Context and Sector Trends
Starling Oncology's results come as the healthcare sector continues a shift toward value-based reimbursement models. The company’s increased revenue guidance, now set at $650 million to $660 million, suggests confidence in its ability to scale patient encounters and pharmaceutical volume. This growth is notable compared to the $142.0 million revenue baseline seen in Q4 2025. A significant upcoming liquidity event includes the expiration of public redeemable warrants on November 12, 2026. This capital structure transition occurs as the company faces a sector landscape defined by rising drug costs and the expansion of the CMS Enhancing Oncology Model, which incentivizes the type of cost-efficient community care Starling provides.
| Date | Announcement | Amount |
|---|---|---|
| 05 Nov 2026 | Q3 2026 consolidated revenue and FY 2026 guidance updateSource: globenewswire.com | $169.8 Million |
| 06 Aug 2026 | Q2 2026 consolidated revenue and FY 2026 guidance updateSource: investors.starlingoncology.com | $161.3 Million |
| 07 May 2026 | Q1 2026 consolidated revenue and FY 2026 guidance reaffirmationSource: stocktitan.net | $147.4 Million |
| 12 Mar 2026 | Q4 2025 consolidated revenue and initial FY 2026 guidanceSource: investors.starlingoncology.com | $142.0 Million |
| 13 Nov 2025 | Q3 2025 consolidated revenue and FY 2025 guidance increaseSource: stocktitan.net | $136.6 Million |
| 13 Aug 2025 | Q2 2025 consolidated revenue and FY 2025 guidance reaffirmationSource: seekingalpha.com | $119.8 Million |
SEC filing by Starling Oncology, Inc. announcing its third-quarter 2026 financial results.
Track Starling Oncology, Inc. live
Get the next Starling Oncology, Inc. SEC filing seconds after it lands.



